Blood Cancer Talks

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser. 

Here are the shownotes:

1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:
2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:
3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):
4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:
5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):
6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:
7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk